High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

August 31, 2015

Conditions
B-cell LymphomaIndolent B-cell Lymphoma
Interventions
DRUG

rituximab

Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER